Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2011

01.06.2011 | Clinical Trial

Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients

verfasst von: I. Gounaris, E. Provenzano, A. L. Vallier, L. Hiller, M. Iddawela, S. Hilborne, K. Taylor, P. Britton, H. M. Earl, R. Sinnatamby

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurements prior to, after 4 cycles (mid-treatment), and at the end of 8 cycles (end-treatment) of chemotherapy were available from a subset of 55 patients enrolled in Neo-tAnGo, a National Cancer Research Network (NCRN) UK neoadjuvant chemotherapy breast cancer trial. Proportional changes in longest diameter (LD) and volume as well as absolute residual size thresholds were examined for their ability to predict pCR or pCR plus minimal residual disease (pCR/MRD). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) and likelihood ratios (LRs) were calculated. Receiver-operator characteristic (ROC) curves and logistic regression models were also constructed. At mid-treatment, neither complete radiological response, nor proportional LD or volume changes were found predictive of final pCR. A small residual tumour volume (≤1 cm3 vs. >1 cm3) at mid-treatment, however, was associated with pCR/MRD (P = 0.014). Sensitivity, specificity, PPV, NPV, LR+ and LR− values were 61%, 77%, 61%, 77%, 2.62 and 0.51, respectively. The area under the ROC curve was 0.689 (P = 0.03). Volume ≤1 cm3 at mid-treatment was found significant in a logistic regression (OR: 0.194, P = 0.011). At end-treatment, no ultrasound measurements were found predictive of pCR or pCR/MRD. In conclusion, proportional tumour size changes (the basis of the RECIST criteria) were not found predictive of good pathological response, although residual volume ≤1 cm3 at mid-treatment was found to be predictive of pCR/MRD. However, multiple volume and LD thresholds were examined and uncorrected P values presented, increasing the possibility of type I errors. Replication in an independent dataset is required.
Literatur
1.
Zurück zum Zitat Li SI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773–2780PubMedCrossRef Li SI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773–2780PubMedCrossRef
2.
Zurück zum Zitat Ravdin P, Cronin K, Howlander N, Berg C, Chlebowski R, Feuer E et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med 356:1670–1674PubMedCrossRef Ravdin P, Cronin K, Howlander N, Berg C, Chlebowski R, Feuer E et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med 356:1670–1674PubMedCrossRef
3.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics 2009. CA Cancer J Clin 59:225–249PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics 2009. CA Cancer J Clin 59:225–249PubMedCrossRef
4.
Zurück zum Zitat Mauri D, Pavlidis N, Ioannidis J (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRef Mauri D, Pavlidis N, Ioannidis J (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRef
5.
Zurück zum Zitat Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed
6.
Zurück zum Zitat Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469PubMed Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469PubMed
7.
Zurück zum Zitat Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320–327PubMedCrossRef Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320–327PubMedCrossRef
8.
Zurück zum Zitat Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422PubMedCrossRef Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422PubMedCrossRef
9.
Zurück zum Zitat von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomised GeparTrio study. J Natl Cancer Inst 100:552–562CrossRef von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomised GeparTrio study. J Natl Cancer Inst 100:552–562CrossRef
10.
Zurück zum Zitat Chapgar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN et al (2006) Accuracy of physical examination, mammography and ultrasonography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy. Ann Surg 243:257–264CrossRef Chapgar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN et al (2006) Accuracy of physical examination, mammography and ultrasonography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy. Ann Surg 243:257–264CrossRef
11.
Zurück zum Zitat Kanazawa T, Akashi-Tanaka S, Iwamoto E, Takasugi M, Shien T, Kinoshita T et al (2005) Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J 11:311–316PubMedCrossRef Kanazawa T, Akashi-Tanaka S, Iwamoto E, Takasugi M, Shien T, Kinoshita T et al (2005) Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J 11:311–316PubMedCrossRef
12.
Zurück zum Zitat Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA et al (2005) Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231–238PubMedCrossRef Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA et al (2005) Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231–238PubMedCrossRef
13.
Zurück zum Zitat Zhu Q, Tannenbaum S, Hedge P, Kane M, Xu C, Kurtzman SH (2008) Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 10:1028–1040PubMed Zhu Q, Tannenbaum S, Hedge P, Kane M, Xu C, Kurtzman SH (2008) Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia 10:1028–1040PubMed
14.
Zurück zum Zitat Singh G, Kumar P, Parshad R, Seith A, Thulkar S, Hosten N (2010) Role of color doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy. Eur J Radiol 75:e158–e162PubMedCrossRef Singh G, Kumar P, Parshad R, Seith A, Thulkar S, Hosten N (2010) Role of color doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy. Eur J Radiol 75:e158–e162PubMedCrossRef
15.
Zurück zum Zitat Earl HM, Vallier A, Hiller L, Fenwick N, Iddawela M, Hughes-Davies L et al (2009) Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 27:s522 Earl HM, Vallier A, Hiller L, Fenwick N, Iddawela M, Hughes-Davies L et al (2009) Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 27:s522
16.
Zurück zum Zitat Prager R, Gee A, Treece G, Berman L (2002) Freehand 3D ultrasound without voxels: volume measurement and visualisation using the Stradx system. Ultrasonics 40:109–115PubMedCrossRef Prager R, Gee A, Treece G, Berman L (2002) Freehand 3D ultrasound without voxels: volume measurement and visualisation using the Stradx system. Ultrasonics 40:109–115PubMedCrossRef
17.
Zurück zum Zitat Treece G, Gee A, Prager R, Cash CJ, Berman L (2003) High definition freehand 3D ultrasound. Ultrasound Med Biol 29:529–546PubMedCrossRef Treece G, Gee A, Prager R, Cash CJ, Berman L (2003) High definition freehand 3D ultrasound. Ultrasound Med Biol 29:529–546PubMedCrossRef
18.
Zurück zum Zitat El-Didi MH, Moneer MM, Khaled HM, Makarem S (2000) Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 30:249–254PubMedCrossRef El-Didi MH, Moneer MM, Khaled HM, Makarem S (2000) Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surg Today 30:249–254PubMedCrossRef
19.
Zurück zum Zitat Huber S, Medl M, Vesely M, Czembirek H, Zuna I, Delorme S (2000) Ultrasonographic tissue characterization in monitoring tumour response to neoadjuvant chemotherapy in locally advanced breast cancer (work in progress). J Ultrasound Med 19:677–686PubMed Huber S, Medl M, Vesely M, Czembirek H, Zuna I, Delorme S (2000) Ultrasonographic tissue characterization in monitoring tumour response to neoadjuvant chemotherapy in locally advanced breast cancer (work in progress). J Ultrasound Med 19:677–686PubMed
20.
Zurück zum Zitat Pinder SE, Provenzano E, Earl E, Ellis IO (2007) Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50:409–417PubMedCrossRef Pinder SE, Provenzano E, Earl E, Ellis IO (2007) Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50:409–417PubMedCrossRef
21.
Zurück zum Zitat Fiorentino C, Berruti A, Bottini A, Bodini M, Brizzi MP, Brunelli A et al (2001) Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat 69:143–151PubMedCrossRef Fiorentino C, Berruti A, Bottini A, Bodini M, Brizzi MP, Brunelli A et al (2001) Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat 69:143–151PubMedCrossRef
22.
Zurück zum Zitat Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ et al (2008) Potential of reduction in total tumour volume measured with 3-D MRI as a prognostic factor for locally-advanced breast cancer patients treated with primary chemotherapy. Breast J 14:523–531PubMedCrossRef Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ et al (2008) Potential of reduction in total tumour volume measured with 3-D MRI as a prognostic factor for locally-advanced breast cancer patients treated with primary chemotherapy. Breast J 14:523–531PubMedCrossRef
23.
Zurück zum Zitat Choi JH, Lim HI, Lee SK, Kim WW, Kim SM, Cho E et al (2010) The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 102:392–397PubMedCrossRef Choi JH, Lim HI, Lee SK, Kim WW, Kim SM, Cho E et al (2010) The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 102:392–397PubMedCrossRef
24.
Zurück zum Zitat Keune J, Jeffe D, Schootman M, Hoffman A, Gillanders W, Aft R (2010) Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg 199:477–484PubMedCrossRef Keune J, Jeffe D, Schootman M, Hoffman A, Gillanders W, Aft R (2010) Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg 199:477–484PubMedCrossRef
25.
Zurück zum Zitat Bear HD, Anderson S, Smith R, Geyer C, Mamounas EP, Fisher B et al (2003) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174PubMedCrossRef Bear HD, Anderson S, Smith R, Geyer C, Mamounas EP, Fisher B et al (2003) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174PubMedCrossRef
26.
Zurück zum Zitat Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ et al (2006) Preoperative evaluation of residual tumour extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12:130–137PubMedCrossRef Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ et al (2006) Preoperative evaluation of residual tumour extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12:130–137PubMedCrossRef
27.
Zurück zum Zitat Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment—benefits of MRI. Breast Cancer Res Treat 72:145–152PubMedCrossRef Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment—benefits of MRI. Breast Cancer Res Treat 72:145–152PubMedCrossRef
28.
Zurück zum Zitat Herrada J, Iyer R, Atkinson EN, Sneige N, Buzdar A, Hortobagyi G (1997) Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumour and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3:1565–1569PubMed Herrada J, Iyer R, Atkinson EN, Sneige N, Buzdar A, Hortobagyi G (1997) Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumour and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3:1565–1569PubMed
29.
Zurück zum Zitat Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14:1371–1379PubMedCrossRef Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14:1371–1379PubMedCrossRef
30.
Zurück zum Zitat Peintinger F, Kuerer H, Anderson K, Boughey J, Meric-Bernstam F, Singletary SE et al (2006) Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13:1443–1449PubMedCrossRef Peintinger F, Kuerer H, Anderson K, Boughey J, Meric-Bernstam F, Singletary SE et al (2006) Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13:1443–1449PubMedCrossRef
31.
Zurück zum Zitat Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR et al (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96:474–480PubMedCrossRef Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR et al (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96:474–480PubMedCrossRef
32.
Zurück zum Zitat Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A (2005) Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer 12:45–51PubMedCrossRef Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A (2005) Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer 12:45–51PubMedCrossRef
33.
Zurück zum Zitat Forouhi P, Walsh JS, Anderson TJ, Chetty U (1994) Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br J Surg 81:223–225PubMedCrossRef Forouhi P, Walsh JS, Anderson TJ, Chetty U (1994) Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br J Surg 81:223–225PubMedCrossRef
34.
Zurück zum Zitat Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Nanasawa T, Matsuo K et al (2001) Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neo-adjuvant chemotherapy. Int J Cancer 96:66–73PubMedCrossRef Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Nanasawa T, Matsuo K et al (2001) Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neo-adjuvant chemotherapy. Int J Cancer 96:66–73PubMedCrossRef
Metadaten
Titel
Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients
verfasst von
I. Gounaris
E. Provenzano
A. L. Vallier
L. Hiller
M. Iddawela
S. Hilborne
K. Taylor
P. Britton
H. M. Earl
R. Sinnatamby
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1454-x

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research and Treatment 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.